Literature DB >> 32170559

Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan.

Li Ni1, Ling Zhou1, Min Zhou2, Jianping Zhao2, Dao Wen Wang3.   

Abstract

In December 2019, an outbreak of novel Coronavirus (2019-nCoV) occurred in Wuhan, Hubei Province, China. By February 14, 2020, it has led to 66 492 confirmed patients in China and high mortality up to ∼2.96% (1123/37 914) in Wuhan. Here we report the first family case of coronavirus disease 2019 (COVID-19) confirmed in Wuhan and treated using the combination of western medicine and Chinese traditional patent medicine Shuanghuanglian oral liquid (SHL). This report describes the identification, diagnosis, clinical course, and management of three cases from a family, suggests the expected therapeutic effects of SHL on COVID-19, and warrants further clinical trials.

Entities:  

Keywords:  COVID-19; Chinese traditional patent medicine; Shuanghuanglian oral liquid; novel coronavirus (2019-nCoV)

Year:  2020        PMID： 32170559      PMCID： PMC7088740          DOI： 10.1007/s11684-020-0757-x

Source DB:  PubMed          Journal:  Front Med        ISSN： 2095-0217            Impact factor:   4.592


  38 in total

1.  Therapeutic Development in COVID-19.

Authors:  Chan Yang; Yuan Huang; Shuwen Liu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Traditional Chinese medicine for combating COVID-19.

Authors:  Kaixian Chen; Hongzhuan Chen
Journal:  Front Med       Date:  2020-07-23       Impact factor: 4.592

Review 3.  Modalities and Mechanisms of Treatment for Coronavirus Disease 2019.

Authors:  Zhihong Zuo; Ting Wu; Liangyu Pan; Chenzhe Zuo; Yingchuo Hu; Xuan Luo; Liping Jiang; Zanxian Xia; Xiaojuan Xiao; Jing Liu; Mao Ye; Meichun Deng
Journal:  Front Pharmacol       Date:  2021-02-08       Impact factor: 5.810

4.  Influence of traditional Chinese medicines on the in vivo metabolism of lopinavir/ritonavir based on UHPLC-MS/MS analysis.

Authors:  Linlin Li; Xinxiang Yu; Dongmin Xie; Ningning Peng; Weilin Wang; Decai Wang; Binglong Li
Journal:  J Pharm Anal       Date:  2021-06-25

Review 5.  Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options.

Authors:  Boxuan Huang; Rongsong Ling; Yifan Cheng; Jieqi Wen; Yarong Dai; Wenjie Huang; Siyan Zhang; Xifeng Lu; Yifeng Luo; Yi-Zhou Jiang
Journal:  Mol Ther Methods Clin Dev       Date:  2020-06-24       Impact factor: 6.698

Review 6.  Recent advances in developing small-molecule inhibitors against SARS-CoV-2.

Authors:  Rong Xiang; Zhengsen Yu; Yang Wang; Lili Wang; Shanshan Huo; Yanbai Li; Ruiying Liang; Qinghong Hao; Tianlei Ying; Yaning Gao; Fei Yu; Shibo Jiang
Journal:  Acta Pharm Sin B       Date:  2021-07-02       Impact factor: 14.903

Review 7.  COVID-19 in Africa: care and protection for frontline healthcare workers.

Authors:  Matthew F Chersich; Glenda Gray; Lee Fairlie; Quentin Eichbaum; Susannah Mayhew; Brian Allwood; Rene English; Fiona Scorgie; Stanley Luchters; Greg Simpson; Marjan Mosalman Haghighi; Minh Duc Pham; Helen Rees
Journal:  Global Health       Date:  2020-05-15       Impact factor: 4.185

8.  Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment.

Authors:  Yan-Hong Shi; Yu-Feng Huang; Wang-Ying Wang; Li Yang; Hua Zhou; Zhen Sang
Journal:  Pharmacol Res       Date:  2020-07-09       Impact factor: 7.658

9.  Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients.

Authors:  Hai-Xia Su; Sheng Yao; Wen-Feng Zhao; Min-Jun Li; Jia Liu; Wei-Juan Shang; Hang Xie; Chang-Qiang Ke; Hang-Chen Hu; Mei-Na Gao; Kun-Qian Yu; Hong Liu; Jing-Shan Shen; Wei Tang; Lei-Ke Zhang; Geng-Fu Xiao; Li Ni; Dao-Wen Wang; Jian-Ping Zuo; Hua-Liang Jiang; Fang Bai; Yan Wu; Yang Ye; Ye-Chun Xu
Journal:  Acta Pharmacol Sin       Date:  2020-07-31       Impact factor: 6.150

Review 10.  Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19).

Authors:  Henu Kumar Verma; Neha Merchant; Manish Kumar Verma; Cansu İlke Kuru; Anand Narayan Singh; Fulden Ulucan; Poonam Verma; Antaripa Bhattacharya; L V K S Bhaskar
Journal:  Biomed J       Date:  2020-07-24       Impact factor: 4.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.